(Q40582076)

English

Bacteremia due to viridans group Streptococci with diminished susceptibility to Levofloxacin among neutropenic patients receiving levofloxacin prophylaxis

scientific article published on 7 May 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Bacteremia due to viridans group Streptococci with diminished susceptibility to Levofloxacin among neutropenic patients receiving levofloxacin prophylaxis (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

1 reference

based on heuristic

inferred from title

2

object named as

Mark R Litzow

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

author name string

Raymund R Razonable

1

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Yasmin Khaliq

3

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Kerryl E Piper

4

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Mark S Rouse

5

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Robin Patel

6

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

language of work or name

0 references

publication date

7 May 2002

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Clinical Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

34

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

1469-1474

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors.

1 reference

https://api.crossref.org/works/10.1086%2F340352

21 January 2018

Serious complications of bacteremia caused by Viridans streptococci in neutropenic patients with cancer.

1 reference

https://api.crossref.org/works/10.1086%2F340352

21 January 2018

Streptococcus mitis sepsis in bone marrow transplant patients receiving oral antimicrobial prophylaxis.

1 reference

https://api.crossref.org/works/10.1086%2F340352

21 January 2018

In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program

1 reference

https://api.crossref.org/works/10.1086%2F340352

21 January 2018

Potencies of newer fluoroquinolones against Viridans group Streptococciisolated in 637 cases of bloodstream infection in the SENTRY Antimicrobial Surveillance Program (1997 to 1999): beyond Canada!

1 reference

https://api.crossref.org/works/10.1086%2F340352

21 January 2018

Antimicrobial activity of gatifloxacin compared to seven other compounds tested against gram-positive organisms isolated at 10 cancer-treatment centers

1 reference

https://api.crossref.org/works/10.1086%2F340352

21 January 2018

Natural history of vancomycin-resistant enterococcal colonization in liver and kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1086%2F340352

21 January 2018

In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans streptococci and genomic organization of the parE-parC region in S. mitis

1 reference

https://api.crossref.org/works/10.1086%2F340352

21 January 2018

Fluoroquinolone resistance associated with target mutations and active efflux in oropharyngeal colonizing isolates of viridans group streptococci

1 reference

https://api.crossref.org/works/10.1086%2F340352

21 January 2018

Trovafloxacin treatment of viridans group Streptococcus experimental endocarditis

1 reference

https://api.crossref.org/works/10.1086%2F340352

21 January 2018

Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci

1 reference

https://api.crossref.org/works/10.1086%2F340352

21 January 2018

Mechanisms responsible for cross-resistance and dichotomous resistance among the quinolones

1 reference

https://api.crossref.org/works/10.1086%2F340352

21 January 2018

Mechanisms of action of antimicrobials: focus on fluoroquinolones

1 reference

https://api.crossref.org/works/10.1086%2F340352

21 January 2018

Bacteremia due to viridans streptococci in neutropenic patients: a review

1 reference

https://api.crossref.org/works/10.1086%2F340352

21 January 2018

Septicemia and Shock Syndrome Due to Viridans Streptococci: A Case-Control Study of Predisposing Factors

1 reference

https://api.crossref.org/works/10.1086%2F340352

21 January 2018

Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice.

1 reference

https://api.crossref.org/works/10.1086%2F340352

21 January 2018

Emergence of vancomycin tolerance in Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1086%2F340352

21 January 2018

Interspecies recombination contributes minimally to fluoroquinolone resistance in Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1086%2F340352

21 January 2018

Identifiers

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40582076&oldid=1903238540"